Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

Stephen G. Swisher, Jack A. Roth, John Nemunaitis, David D. Lawrence, Bonnie L. Kemp, Cesar H. Carrasco, Dee G. Connors, Adel K. El-Naggar, Frank Fossella, Bonnie S. Glisson, Waun K. Hong, Fadlo R. Khuri, Jonathan M. Kurie, Jack J. Lee, Jin S. Lee, Michael Mack, James A. Merritt, Dao M. Nguyen, Jonathan C. Nesbitt, Roman Perez-Soler & 11 others Katherine M W Pisters, Joe B. Putnam, William R. Richli, Michael Savin, David S. Schrump, Dong M. Shin, Allan Shulkin, Garrett L. Walsh, Juliette Wait, David Weill, M. Kimberly A Waugh

Research output: Contribution to journalArticle

436 Citations (Scopus)

Abstract

Background: Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing wild-type p53 complementary DNA (Ad-p53). Therefore, in a phase I clinical trial, we administered Ad-p53 to 28 patients with nonsmall-cell lung cancer (NSCLC) whose cancers had progressed on conventional treatments. Methods: Patients received up to six, monthly intratumoral injections of Adp53 by use of computed tomography-guided percutaneous fine-needle injection (23 patients) or bronchoscopy (five patients). The doses ranged from 106 plaque-forming units (PFU) to 1011 PFU. Results: Polymerase chain reaction (PCR) analysis showed the presence of adenovirus vector DNA in 18 (86%) of 21 patients with evaluable posttreatment biopsy specimens; vector-specific p53 messenger RNA was detected by means of reverse transcription-PCR analysis in 12 (46%) of 26 patients. Apoptosis (programmed cell death) was demonstrated by increased terminal deoxynucleotide transferase-mediated biotin uridine triphosphate nick-end labeling (TUNEL) staining in posttreatment biopsy specimens from 11 patients. Vector-related toxicity was minimal (National Cancer Institute's Common Toxicity Criteria: grade 3 = one patient; grade 4 = no patients) in 84 courses of treatment, despite repeated injections (up to six) in 23 patients. Therapeutic activity in 25 evaluable patients included partial responses in two patients (8%) and disease stabilization (range, 2- 14 months) in 16 patients (64%); the remaining seven patients (28%) exhibited disease progression. Conclusions: Repeated intratumoral injections of Adp53 appear to be well tolerated, result in transgene expression of wild-type p53, and seem to mediate antitumor activity in a subset of patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)763-771
Number of pages9
JournalJournal of the National Cancer Institute
Volume91
Issue number9
StatePublished - May 5 1999
Externally publishedYes

Fingerprint

p53 Genes
Adenoviridae
Non-Small Cell Lung Carcinoma
Injections
Biopsy
Polymerase Chain Reaction
Clinical Trials, Phase I
Uridine Triphosphate
National Cancer Institute (U.S.)
Bronchoscopy
Biotin
Transferases
Transgenes
Reverse Transcription
Needles
Disease Progression
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., ... Waugh, M. K. A. (1999). Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 91(9), 763-771.

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. / Swisher, Stephen G.; Roth, Jack A.; Nemunaitis, John; Lawrence, David D.; Kemp, Bonnie L.; Carrasco, Cesar H.; Connors, Dee G.; El-Naggar, Adel K.; Fossella, Frank; Glisson, Bonnie S.; Hong, Waun K.; Khuri, Fadlo R.; Kurie, Jonathan M.; Lee, Jack J.; Lee, Jin S.; Mack, Michael; Merritt, James A.; Nguyen, Dao M.; Nesbitt, Jonathan C.; Perez-Soler, Roman; Pisters, Katherine M W; Putnam, Joe B.; Richli, William R.; Savin, Michael; Schrump, David S.; Shin, Dong M.; Shulkin, Allan; Walsh, Garrett L.; Wait, Juliette; Weill, David; Waugh, M. Kimberly A.

In: Journal of the National Cancer Institute, Vol. 91, No. 9, 05.05.1999, p. 763-771.

Research output: Contribution to journalArticle

Swisher, SG, Roth, JA, Nemunaitis, J, Lawrence, DD, Kemp, BL, Carrasco, CH, Connors, DG, El-Naggar, AK, Fossella, F, Glisson, BS, Hong, WK, Khuri, FR, Kurie, JM, Lee, JJ, Lee, JS, Mack, M, Merritt, JA, Nguyen, DM, Nesbitt, JC, Perez-Soler, R, Pisters, KMW, Putnam, JB, Richli, WR, Savin, M, Schrump, DS, Shin, DM, Shulkin, A, Walsh, GL, Wait, J, Weill, D & Waugh, MKA 1999, 'Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer', Journal of the National Cancer Institute, vol. 91, no. 9, pp. 763-771.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. Journal of the National Cancer Institute. 1999 May 5;91(9):763-771.
Swisher, Stephen G. ; Roth, Jack A. ; Nemunaitis, John ; Lawrence, David D. ; Kemp, Bonnie L. ; Carrasco, Cesar H. ; Connors, Dee G. ; El-Naggar, Adel K. ; Fossella, Frank ; Glisson, Bonnie S. ; Hong, Waun K. ; Khuri, Fadlo R. ; Kurie, Jonathan M. ; Lee, Jack J. ; Lee, Jin S. ; Mack, Michael ; Merritt, James A. ; Nguyen, Dao M. ; Nesbitt, Jonathan C. ; Perez-Soler, Roman ; Pisters, Katherine M W ; Putnam, Joe B. ; Richli, William R. ; Savin, Michael ; Schrump, David S. ; Shin, Dong M. ; Shulkin, Allan ; Walsh, Garrett L. ; Wait, Juliette ; Weill, David ; Waugh, M. Kimberly A. / Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. In: Journal of the National Cancer Institute. 1999 ; Vol. 91, No. 9. pp. 763-771.
@article{032813c33f75427a95f120e847f9ab90,
title = "Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer",
abstract = "Background: Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing wild-type p53 complementary DNA (Ad-p53). Therefore, in a phase I clinical trial, we administered Ad-p53 to 28 patients with nonsmall-cell lung cancer (NSCLC) whose cancers had progressed on conventional treatments. Methods: Patients received up to six, monthly intratumoral injections of Adp53 by use of computed tomography-guided percutaneous fine-needle injection (23 patients) or bronchoscopy (five patients). The doses ranged from 106 plaque-forming units (PFU) to 1011 PFU. Results: Polymerase chain reaction (PCR) analysis showed the presence of adenovirus vector DNA in 18 (86{\%}) of 21 patients with evaluable posttreatment biopsy specimens; vector-specific p53 messenger RNA was detected by means of reverse transcription-PCR analysis in 12 (46{\%}) of 26 patients. Apoptosis (programmed cell death) was demonstrated by increased terminal deoxynucleotide transferase-mediated biotin uridine triphosphate nick-end labeling (TUNEL) staining in posttreatment biopsy specimens from 11 patients. Vector-related toxicity was minimal (National Cancer Institute's Common Toxicity Criteria: grade 3 = one patient; grade 4 = no patients) in 84 courses of treatment, despite repeated injections (up to six) in 23 patients. Therapeutic activity in 25 evaluable patients included partial responses in two patients (8{\%}) and disease stabilization (range, 2- 14 months) in 16 patients (64{\%}); the remaining seven patients (28{\%}) exhibited disease progression. Conclusions: Repeated intratumoral injections of Adp53 appear to be well tolerated, result in transgene expression of wild-type p53, and seem to mediate antitumor activity in a subset of patients with advanced NSCLC.",
author = "Swisher, {Stephen G.} and Roth, {Jack A.} and John Nemunaitis and Lawrence, {David D.} and Kemp, {Bonnie L.} and Carrasco, {Cesar H.} and Connors, {Dee G.} and El-Naggar, {Adel K.} and Frank Fossella and Glisson, {Bonnie S.} and Hong, {Waun K.} and Khuri, {Fadlo R.} and Kurie, {Jonathan M.} and Lee, {Jack J.} and Lee, {Jin S.} and Michael Mack and Merritt, {James A.} and Nguyen, {Dao M.} and Nesbitt, {Jonathan C.} and Roman Perez-Soler and Pisters, {Katherine M W} and Putnam, {Joe B.} and Richli, {William R.} and Michael Savin and Schrump, {David S.} and Shin, {Dong M.} and Allan Shulkin and Walsh, {Garrett L.} and Juliette Wait and David Weill and Waugh, {M. Kimberly A}",
year = "1999",
month = "5",
day = "5",
language = "English (US)",
volume = "91",
pages = "763--771",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

AU - Swisher, Stephen G.

AU - Roth, Jack A.

AU - Nemunaitis, John

AU - Lawrence, David D.

AU - Kemp, Bonnie L.

AU - Carrasco, Cesar H.

AU - Connors, Dee G.

AU - El-Naggar, Adel K.

AU - Fossella, Frank

AU - Glisson, Bonnie S.

AU - Hong, Waun K.

AU - Khuri, Fadlo R.

AU - Kurie, Jonathan M.

AU - Lee, Jack J.

AU - Lee, Jin S.

AU - Mack, Michael

AU - Merritt, James A.

AU - Nguyen, Dao M.

AU - Nesbitt, Jonathan C.

AU - Perez-Soler, Roman

AU - Pisters, Katherine M W

AU - Putnam, Joe B.

AU - Richli, William R.

AU - Savin, Michael

AU - Schrump, David S.

AU - Shin, Dong M.

AU - Shulkin, Allan

AU - Walsh, Garrett L.

AU - Wait, Juliette

AU - Weill, David

AU - Waugh, M. Kimberly A

PY - 1999/5/5

Y1 - 1999/5/5

N2 - Background: Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing wild-type p53 complementary DNA (Ad-p53). Therefore, in a phase I clinical trial, we administered Ad-p53 to 28 patients with nonsmall-cell lung cancer (NSCLC) whose cancers had progressed on conventional treatments. Methods: Patients received up to six, monthly intratumoral injections of Adp53 by use of computed tomography-guided percutaneous fine-needle injection (23 patients) or bronchoscopy (five patients). The doses ranged from 106 plaque-forming units (PFU) to 1011 PFU. Results: Polymerase chain reaction (PCR) analysis showed the presence of adenovirus vector DNA in 18 (86%) of 21 patients with evaluable posttreatment biopsy specimens; vector-specific p53 messenger RNA was detected by means of reverse transcription-PCR analysis in 12 (46%) of 26 patients. Apoptosis (programmed cell death) was demonstrated by increased terminal deoxynucleotide transferase-mediated biotin uridine triphosphate nick-end labeling (TUNEL) staining in posttreatment biopsy specimens from 11 patients. Vector-related toxicity was minimal (National Cancer Institute's Common Toxicity Criteria: grade 3 = one patient; grade 4 = no patients) in 84 courses of treatment, despite repeated injections (up to six) in 23 patients. Therapeutic activity in 25 evaluable patients included partial responses in two patients (8%) and disease stabilization (range, 2- 14 months) in 16 patients (64%); the remaining seven patients (28%) exhibited disease progression. Conclusions: Repeated intratumoral injections of Adp53 appear to be well tolerated, result in transgene expression of wild-type p53, and seem to mediate antitumor activity in a subset of patients with advanced NSCLC.

AB - Background: Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing wild-type p53 complementary DNA (Ad-p53). Therefore, in a phase I clinical trial, we administered Ad-p53 to 28 patients with nonsmall-cell lung cancer (NSCLC) whose cancers had progressed on conventional treatments. Methods: Patients received up to six, monthly intratumoral injections of Adp53 by use of computed tomography-guided percutaneous fine-needle injection (23 patients) or bronchoscopy (five patients). The doses ranged from 106 plaque-forming units (PFU) to 1011 PFU. Results: Polymerase chain reaction (PCR) analysis showed the presence of adenovirus vector DNA in 18 (86%) of 21 patients with evaluable posttreatment biopsy specimens; vector-specific p53 messenger RNA was detected by means of reverse transcription-PCR analysis in 12 (46%) of 26 patients. Apoptosis (programmed cell death) was demonstrated by increased terminal deoxynucleotide transferase-mediated biotin uridine triphosphate nick-end labeling (TUNEL) staining in posttreatment biopsy specimens from 11 patients. Vector-related toxicity was minimal (National Cancer Institute's Common Toxicity Criteria: grade 3 = one patient; grade 4 = no patients) in 84 courses of treatment, despite repeated injections (up to six) in 23 patients. Therapeutic activity in 25 evaluable patients included partial responses in two patients (8%) and disease stabilization (range, 2- 14 months) in 16 patients (64%); the remaining seven patients (28%) exhibited disease progression. Conclusions: Repeated intratumoral injections of Adp53 appear to be well tolerated, result in transgene expression of wild-type p53, and seem to mediate antitumor activity in a subset of patients with advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0033526357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033526357&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 763

EP - 771

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -